Inoviq Ltd · ASX:IIQ
Inoviq — ASX Small & Mid-Cap Conference (September 2023)
12 slides from Inoviq's conference presentation, Sep 20, 2023
Slide 1: Investor Presentation – ASX Small & Mid-Cap Conference
Investor Presentation ASX Small & Mid-Cap Conference ASX: IIQ | 20 September 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expressed in, or implied by
Slide 3: Company snapshot
Company snapshot $ INOVIQ is developing next-generation precision diagnostics Precision Disruptive Deep and exosome solutions to transform the diagnosis and focus technology pipeline treatment of cancer and other diseases Financial information (ASX:IIQ) Precision diagnostic and Proprietary technolog
Slide 4: Products and pipeline: multistage research tools and cancer diagnostic portfolio
Products and pipeline | multistage research tools and cancer diagnostic portfolio • Blood tests for earlier and more accurate detection of breast, ovarian and other cancers • Exosome research tools for exosome isolation, biomarker discovery and diagnostics development PRODUCT INDICATION USE RESEARCH
Slide 5: SubB2M/CA15-3 test | Breast Cancer monitoring
SubB2M/CA15-3 test | Breast Cancer monitoring Clinical-stage and progressing towards market-ready for LDT partnering by Dec 2023 • #1 cancer in women Development stage Breast cancer • 2.3m new cases of breast cancer worldwide pa1 • 7.8m survivors (5-year)1 Feasibility Completed • Earlier and more ac
Slide 6: SubB2M/CA15-3 Test: data and plans
SubB2M/CA15-3 Test: data and plans SubB2M/CA15-3 and comparator CA15-3 test Data | Clinical validation study performance summary Breast Cancer All Stages SubB2M Comparator • Retrospective, case-control, clinical validation study in 483-samples AUC 0.93 0.70 demonstrated SubB2M/CA15-3 test detected b
Slide 7: SubB2M/CA125 Test | Ovarian Cancer monitoring
SubB2M/CA125 Test | Ovarian Cancer monitoring Progressing towards clinical validation • #8 cancer in women & deadliest gynaecological cancer Development stage Ovarian cancer • 314k new cases of ovarian cancer worldwide pa1 • 823k survivors (5-year)1 Feasibility Completed • Earlier and more accurate
Slide 8: EXO-OC Test | Exosome-based Ovarian Cancer screening
EXO-OC Test | Exosome-based Ovarian Cancer screening1,2,3 Developing an accurate and reliable test for early detection of ovarian cancer • #8 cancer in women & deadliest gynaecological cancer Development stage Ovarian cancer • 314k new cases of ovarian cancer worldwide pa4 • 823k survivors (5-year)4
Slide 9: Exosomes | Diagnostic and therapeutic potential
Exosomes | Diagnostic and therapeutic potential • Exosomes are released by cells and perform key roles in intercellular communication, immune regulation and pathogenesis • Diseases elicit changes in the release of exosomes and their molecular cargo (DNA, RNA and proteins) • Exosomes can be isolated
Slide 10: EXO-NET research tools and services
EXO-NET research tools and services | commercially available EXO-NET PAN- CUSTOMISED EXOSOME BIOMARKER DIAGNOSTICS EXOSOME CAPTURE EXO-NET TOOLS ISOLATION DISCOVERY DEVELOPMENT EXO-NET is a research Design custom EV isolation using Biomarker discovery EV-based clinical tool for fast, efficient & EXO
Slide 11: Milestones and catalysts
Milestones and catalysts SubB2M and EXO-NET programs moving towards key inflection points H2 CY 2023 H1 CY 2024 ✓ EXO-NET co-marketing agreement with Promega Commercial progress SubB2M/CA15-3 LDT ✓ Results of EXO-OC equivalence study in plasma and serum (n=250) Results SubB2M/CA125 OC clinical valid
Slide 12: Contacts
Contacts INOVIQ Ltd Dr Leearne Hinch Chief Executive Officer 23 Normanby Road Notting Hill VIC 3168 e. lhinch@inoviq.com Australia p. +61 3 9548 7586 e. info@inoviq.com w. www.inoviq.com 12
INOVIQ — ASX Small & Mid-Cap Conference (September 2023) on 6ix